MoneyWorks4Me

Biocon informs about company statement

04 Mar 2024 Evaluate

Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

411.40 -6.40 (-1.53%)
28-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1920.10
Dr. Reddys Labs. 1177.80
Cipla 1418.00
Lupin 2175.00
Zydus Lifesciences 1187.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: